Red cell substitutes: An update

The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of emergency medicine 1985-08, Vol.14 (8), p.798-803
Hauptverfasser: Gould, Steven A, Sehgal, Lakshman R, Rosen, Arthur L, Sehgal, Hansa L, Moss, Gerald S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 803
container_issue 8
container_start_page 798
container_title Annals of emergency medicine
container_volume 14
creator Gould, Steven A
Sehgal, Lakshman R
Rosen, Arthur L
Sehgal, Hansa L
Moss, Gerald S
description The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.
doi_str_mv 10.1016/S0196-0644(85)80061-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76245269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196064485800615</els_id><sourcerecordid>76245269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotVZ_QnFWoovRm0ySSdyUUnxBQfCxDjPJDUTaTp1kBP-90wfdurqLc849936EjCncUqDy7h2oljlIzq-VuFEAkubiiAwp6DKXpYRjMjxYTslZjF8AoDmjAzLgwIQu2ZBcvqHLLC4WWezqmELqEsb7bLrKurWrEp6TE18tIl7s54h8Pj58zJ7z-evTy2w6z20hIeUVeu9rKUFDWdaeUQ2UFzVwEAheSe8LVVlBNRaqKCqvnVacW1da6rX1rBiRq93eddt8dxiTWYa4uataYdNFU0rGBZO6N4qd0bZNjC16s27Dsmp_DQWzAWO2YMzma6OE2YIxos-N9wVdvUR3SO1J9Ppkp2P_5U_A1kQbcGXRhRZtMq4J_zT8AVyfcJM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76245269</pqid></control><display><type>article</type><title>Red cell substitutes: An update</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</creator><creatorcontrib>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</creatorcontrib><description>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</description><identifier>ISSN: 0196-0644</identifier><identifier>EISSN: 1097-6760</identifier><identifier>DOI: 10.1016/S0196-0644(85)80061-5</identifier><identifier>PMID: 4025972</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Animals ; Blood Substitutes - metabolism ; Blood Substitutes - therapeutic use ; Drug Evaluation ; fluorocarbons ; Fluorocarbons - metabolism ; Fluorocarbons - therapeutic use ; hemorrhagic shock ; Humans ; Oxygen Consumption ; oxygen transport ; Papio ; polyhemoglobin ; Rats ; Shock, Hemorrhagic - drug therapy</subject><ispartof>Annals of emergency medicine, 1985-08, Vol.14 (8), p.798-803</ispartof><rights>1985 American College of Emergency Physicians</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</citedby><cites>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0196-0644(85)80061-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4025972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gould, Steven A</creatorcontrib><creatorcontrib>Sehgal, Lakshman R</creatorcontrib><creatorcontrib>Rosen, Arthur L</creatorcontrib><creatorcontrib>Sehgal, Hansa L</creatorcontrib><creatorcontrib>Moss, Gerald S</creatorcontrib><title>Red cell substitutes: An update</title><title>Annals of emergency medicine</title><addtitle>Ann Emerg Med</addtitle><description>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</description><subject>Animals</subject><subject>Blood Substitutes - metabolism</subject><subject>Blood Substitutes - therapeutic use</subject><subject>Drug Evaluation</subject><subject>fluorocarbons</subject><subject>Fluorocarbons - metabolism</subject><subject>Fluorocarbons - therapeutic use</subject><subject>hemorrhagic shock</subject><subject>Humans</subject><subject>Oxygen Consumption</subject><subject>oxygen transport</subject><subject>Papio</subject><subject>polyhemoglobin</subject><subject>Rats</subject><subject>Shock, Hemorrhagic - drug therapy</subject><issn>0196-0644</issn><issn>1097-6760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUhYMotVZ_QnFWoovRm0ySSdyUUnxBQfCxDjPJDUTaTp1kBP-90wfdurqLc849936EjCncUqDy7h2oljlIzq-VuFEAkubiiAwp6DKXpYRjMjxYTslZjF8AoDmjAzLgwIQu2ZBcvqHLLC4WWezqmELqEsb7bLrKurWrEp6TE18tIl7s54h8Pj58zJ7z-evTy2w6z20hIeUVeu9rKUFDWdaeUQ2UFzVwEAheSe8LVVlBNRaqKCqvnVacW1da6rX1rBiRq93eddt8dxiTWYa4uataYdNFU0rGBZO6N4qd0bZNjC16s27Dsmp_DQWzAWO2YMzma6OE2YIxos-N9wVdvUR3SO1J9Ppkp2P_5U_A1kQbcGXRhRZtMq4J_zT8AVyfcJM</recordid><startdate>198508</startdate><enddate>198508</enddate><creator>Gould, Steven A</creator><creator>Sehgal, Lakshman R</creator><creator>Rosen, Arthur L</creator><creator>Sehgal, Hansa L</creator><creator>Moss, Gerald S</creator><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198508</creationdate><title>Red cell substitutes: An update</title><author>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Animals</topic><topic>Blood Substitutes - metabolism</topic><topic>Blood Substitutes - therapeutic use</topic><topic>Drug Evaluation</topic><topic>fluorocarbons</topic><topic>Fluorocarbons - metabolism</topic><topic>Fluorocarbons - therapeutic use</topic><topic>hemorrhagic shock</topic><topic>Humans</topic><topic>Oxygen Consumption</topic><topic>oxygen transport</topic><topic>Papio</topic><topic>polyhemoglobin</topic><topic>Rats</topic><topic>Shock, Hemorrhagic - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gould, Steven A</creatorcontrib><creatorcontrib>Sehgal, Lakshman R</creatorcontrib><creatorcontrib>Rosen, Arthur L</creatorcontrib><creatorcontrib>Sehgal, Hansa L</creatorcontrib><creatorcontrib>Moss, Gerald S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gould, Steven A</au><au>Sehgal, Lakshman R</au><au>Rosen, Arthur L</au><au>Sehgal, Hansa L</au><au>Moss, Gerald S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Red cell substitutes: An update</atitle><jtitle>Annals of emergency medicine</jtitle><addtitle>Ann Emerg Med</addtitle><date>1985-08</date><risdate>1985</risdate><volume>14</volume><issue>8</issue><spage>798</spage><epage>803</epage><pages>798-803</pages><issn>0196-0644</issn><eissn>1097-6760</eissn><abstract>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>4025972</pmid><doi>10.1016/S0196-0644(85)80061-5</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0196-0644
ispartof Annals of emergency medicine, 1985-08, Vol.14 (8), p.798-803
issn 0196-0644
1097-6760
language eng
recordid cdi_proquest_miscellaneous_76245269
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Blood Substitutes - metabolism
Blood Substitutes - therapeutic use
Drug Evaluation
fluorocarbons
Fluorocarbons - metabolism
Fluorocarbons - therapeutic use
hemorrhagic shock
Humans
Oxygen Consumption
oxygen transport
Papio
polyhemoglobin
Rats
Shock, Hemorrhagic - drug therapy
title Red cell substitutes: An update
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Red%20cell%20substitutes:%20An%20update&rft.jtitle=Annals%20of%20emergency%20medicine&rft.au=Gould,%20Steven%20A&rft.date=1985-08&rft.volume=14&rft.issue=8&rft.spage=798&rft.epage=803&rft.pages=798-803&rft.issn=0196-0644&rft.eissn=1097-6760&rft_id=info:doi/10.1016/S0196-0644(85)80061-5&rft_dat=%3Cproquest_cross%3E76245269%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76245269&rft_id=info:pmid/4025972&rft_els_id=S0196064485800615&rfr_iscdi=true